top of page


Fresenius and WuXi Biologics agree development partnership covering up to 37 biosimilar candidates
Fresenius has entered an exclusive development agreement with WuXi Biologics covering options for up to 37 biosimilar candidates, potentially more than doubling its combined marketed and pipeline portfolio.

nuaxia
Nov 32 min read


FDA approves Sun Pharma Ilumya for adults with active psoriatic arthritis
The FDA has approved Sun Pharma's Ilumya for adults with active psoriatic arthritis, expanding the IL-23 inhibitor beyond its established plaque psoriasis indication.

nuaxia
Nov 22 min read


Adalvo acquires Enzene romiplostim biosimilar programme targeting global Nplate market
Adalvo has acquired Enzene's romiplostim biosimilar programme, expanding its complex biologics portfolio with a candidate referencing Nplate for immune thrombocytopenia.

nuaxia
Oct 282 min read


Aptar Pharma acquires Pulmotree to expand next-generation pulmonary drug delivery technology
Aptar Pharma has acquired German inhalation technology specialist Pulmotree, adding its Kolibri platform to expand next-generation pulmonary drug delivery capabilities.

nuaxia
Oct 282 min read


Samsung Bioepis and Teva expand biosimilars partnership to up to six candidates
Samsung Bioepis and Teva have expanded their biosimilars collaboration to cover two named programmes and options for up to four additional candidates.

nuaxia
Oct 22 min read


Sandoz and mAbxience partner on global emicizumab biosimilar programme
Sandoz and mAbxience have entered a global collaboration to develop, manufacture and commercialise a proposed biosimilar to Roche's haemophilia medicine Hemlibra.

nuaxia
Sep 222 min read


Roche and Dualitas enter bispecific discovery collaboration worth more than $1bn
Roche and Dualitas Therapeutics have entered a large-scale bispecific antibody discovery collaboration potentially worth more than $1 billion across immunology and inflammation programmes.

nuaxia
Sep 182 min read


Piramal Pharma completes acquisition of controlling stake in Yapan Bio to expand biologics CDMO capabilities
The acquisition makes Yapan Bio a Piramal Pharma subsidiary, strengthening the company's integrated biologics development and manufacturing offering for vaccines, biologics and antibody-drug conjugates.

nuaxia
Aug 202 min read


Alteogen signs $365 million Hybrozyme licensing deal for subcutaneous biologic
The agreement gives an undisclosed global pharmaceutical company worldwide rights to use Alteogen’s ALT-B4 technology to develop and commercialise a subcutaneous formulation of an existing biologic.

nuaxia
Aug 72 min read


FDA proposes streamlined nonclinical safety studies for antibody-drug conjugates and other oncology biologics
The draft guidance could reduce reliance on animal studies for some oncology products while increasing the importance of analytical characterisation and weight-of-evidence approaches during development.

nuaxia
Aug 72 min read
bottom of page